Decibel Therapeutics

81 articles with Decibel Therapeutics

• Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

  3/21/2023

  Decibel Therapeutics today announced the appointment of Matthew Kapusta to its Board of Directors.

• Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

  3/14/2023

  Decibel Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference

  2/16/2023

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16, 2023 at 9:20 a.m. E.T.

• Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

  2/9/2023

  Decibel Therapeutics today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

• Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

  1/24/2023

  Decibel Therapeutics today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

• Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update

  11/9/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO

  11/2/2022

  Decibel Therapeutics announced the submission of Clinical Trial Applications to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom and the Spanish Agency of Medicines and Medical Devices for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

• Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

  10/17/2022

  Decibel Therapeutics today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is designed to provide durable hearing in individuals born with profound congenital hearing loss due to an otoferlin deficiency.

• Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

  9/22/2022

  Decibel Therapeutics today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022, at 10:00 a.m. ET in New York, NY.

• Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO

  9/20/2022

  Decibel Therapeutics announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable restoration of hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

• Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update

  8/10/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference

  6/3/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET.

• Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.

• Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update

  5/12/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting

  5/2/2022

  Decibel Therapeutics announced today that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held virtually and in Washington D.C. May 15-19, 2022.

• Decibel Therapeutics to Participate in Upcoming Investor Conferences - Mar 22, 2022

  3/22/2022

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in the following upcoming virtual investor conferences in March.

• Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

  3/18/2022

  Decibel Therapeutics today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

• Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

  2/10/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference,

• Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline

  2/9/2022

  Decibel Therapeutics (Nasdaq: DBTX), announced the presentation of preclinical data on its lead gene therapy product candidate, DB-OTO.

• Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting

  1/31/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 45th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO).